CEO Interview: Advancing Disease-Modifying Treatments for Parkinson’s Disease

Our CEO, Simon Mølgaard, was recently interviewed by Biostock in connection with an important milestone for Teitur Trophics: the initiation of dosing of the first Parkinson’s disease patients in our Phase I clinical trial.

In the interview, Simon discusses Teitur’s approach to Parkinson’s disease, which focuses on addressing the underlying mechanisms of neurodegeneration rather than symptom management alone. The article also provides insight into our lead candidate, TT-P34, and our broader strategy for developing disease-modifying therapies.

‍